1. Home
  2. VS vs GDTC Comparison

VS vs GDTC Comparison

Compare VS & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Versus Systems Inc.

VS

Versus Systems Inc.

HOLD

Current Price

$1.35

Market Cap

9.3M

Sector

Technology

ML Signal

HOLD

Logo CytoMed Therapeutics Limited

GDTC

CytoMed Therapeutics Limited

HOLD

Current Price

$0.88

Market Cap

10.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VS
GDTC
Founded
2013
2018
Country
United States
Singapore
Employees
5
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.3M
10.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
VS
GDTC
Price
$1.35
$0.88
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
60.3K
8.1K
Earning Date
04-15-2026
04-24-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.75
$0.68
52 Week High
$2.72
$3.68

Technical Indicators

Market Signals
Indicator
VS
GDTC
Relative Strength Index (RSI) 45.18 37.53
Support Level $1.17 $0.70
Resistance Level $1.78 $1.07
Average True Range (ATR) 0.13 0.06
MACD -0.02 -0.01
Stochastic Oscillator 8.93 15.43

Price Performance

Historical Comparison
VS
GDTC

About VS Versus Systems Inc.

Versus Systems Inc operates within the technology sector, focusing on engagement-enhancing solutions through its proprietary prizing and promotions platform. This technology enables developers and content creators across streaming, live events, broadcast, gaming, and other media to integrate real-world prizes into their experiences, fostering greater consumer interaction and providing a compelling opportunity for brand partners and advertisers. The company operates in Canada and the USA.

About GDTC CytoMed Therapeutics Limited

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.

Share on Social Networks: